ClinicalTrials.gg
CompletedNCT03210532Updated Feb 1, 2018

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

A Phase 3 interventional study of Telmisartan + Amlodipine + Rosuvastatin and Telmisartan + Amlodipine in Hypertension and Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-02-01.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
59th of 99
129 · median 184
Started
2016
with 1 other
Phase 3
40 of 99
none open now
Registered
77th of 99
by date
Lead sponsor
2 of 99
Daewon Pharmaceutical Co., Ltd.

Among the 99 studies testing telmisartan in Hypertension, this one is the 59th largest by enrollment, is one of 2 that started in 2016, is one of 40 in phase 3, and was the 77th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia

03

Conditions studied

  • Hypertension
  • Dyslipidemia
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults both male and female who are ≥19,\<80 years old
  • at screening, 140mmHg≤ SBP\<180mmHg \& 90mmHg≤ DBP\<110mmHg \& LDL-C≤250mg/dL \& triglyceride\<400mg/dL

Exclusion criteria

Exclusion Criteria:

  • at screening, the difference BP of one-side arm is SBP ≥ 20mmHg and DBP ≥ 10mmHg
  • secondary hypertension or secondary dyslipidemia
  • patients who have uncontrolled diabetes melitus, hyper/hypothyroidism or cardiac disease
  • women who are pregnant or lactating
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Test

    qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)

    Drug: Telmisartan + Amlodipine + Rosuvastatin

  • Active comparator
    Reference 1

    qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)

    Drug: Telmisartan + Rosuvastatin

  • Active comparator
    Reference 2

    qd PO,Twynsta(telmisartan/amlodipine)

    Drug: Telmisartan + Amlodipine

Interventions

  • DrugTelmisartan + Amlodipine + Rosuvastatin

    Drug pages: Telmisartan · Amlodipine · Rosuvastatin

    Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo

  • DrugTelmisartan + Amlodipine

    Drug pages: Telmisartan · Amlodipine

    Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo

  • DrugTelmisartan + Rosuvastatin

    Drug pages: Telmisartan · Rosuvastatin

    Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo

06

What researchers measure

Primary outcomes

  1. Change of MSSBP(Mean Sit Systolic Blood Pressure) from baseline

    Time frame: 8-week

  2. Change of LDL-C(Low Density Lipid Cholesterol) from baseline

    Time frame: 8-week

07

Study locations

1 site
  • Sevrance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Sep 2017, 11 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 11 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2016
First posted
Jul 7, 2017
StartActual
Oct 7, 2016
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Last update
Feb 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03210532
Responsible party
Sponsor
First posted
Jul 7, 2017
Start date
Oct 7, 2016
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Feb 1, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Rosuvastatin

Start the discussion